Cholesterol Nanoparticle Carrier for Liver Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems face challenges in achieving high uptake and stability of nucleic acid-based drugs in the body, leading to low efficacy and increased side effects due to rapid degradation and immune responses, particularly when targeting hepatocytes for liver diseases.
Innovation Solution
A liver-specific drug delivery carrier comprising a nucleic acid nanoparticle and cholesterol, which forms a protein corona upon administration, enhancing targeting specificity and stability by binding to serum proteins like lipoproteins, allowing for efficient delivery to hepatocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acid-based drugs are administered directly into the body, then the drugs can reach the target site, but the uptake rate is extremely low and the drugs are easily hydrolyzed or destroyed by enzymes
Solution Approach 1:
The patent uses a composite delivery system consisting of lipid nanoparticles encapsulating nucleic acid drugs. The lipid nanoparticle composite protects the nucleic acid from enzymatic degradation while providing cellular uptake mechanisms, thereby simultaneously improving both drug stability and uptake rate.
Solution Approach 2:
The lipid nanoparticle acts as an intermediary carrier between the nucleic acid drug and the target hepatocytes. This mediator protects the drug from degradation in the bloodstream while facilitating cellular entry through endocytosis, resolving the contradiction between stability and uptake efficiency.
2Duration of action of stationary object
If nucleic acid drugs are repeatedly administered, then therapeutic effects can be maintained, but immune responses are frequently induced and hypersensitivity reactions occur
Solution Approach 1:
The lipid nanoparticle serves as a biocompatible intermediary that masks the immunogenic nature of the nucleic acid drug. This carrier reduces immune recognition and hypersensitivity reactions while maintaining therapeutic efficacy over multiple administrations.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the drug delivery system by using lipid nanoparticles with specific size, charge, and composition characteristics. These parameter changes reduce immune system recognition and allow for repeated administrations without inducing severe immune responses.
3Reliability
If existing polymeric prodrugs are used to target hepatocytes, then liver targeting is increased, but the stability and immunogenicity of the drug when the polymer is degraded are not accurately reported
Solution Approach 1:
The patent employs lipid nanoparticle composites with well-defined compositions and degradation characteristics. Unlike polymeric prodrugs, the lipid-based system provides predictable degradation into biocompatible fatty acids and glycerol, ensuring known stability profiles and reduced immunogenicity while maintaining liver targeting capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The carrier significantly increases the delivery of drugs to liver tissue, reducing side effects and improving therapeutic outcomes for liver diseases by enhancing the stability and specificity of nucleic acid-based therapies.
Implementation Method 1
which forms a protein corona upon administration, enhancing targeting specificity and stability by binding to serum proteins like lipoproteins
Data Source
AI summary
The present invention relates to a liver-specific drug delivery carrier comprising a nucleic acid nanoparticle and cholesterol; a liver-specific complex; a pharmaceutical composition for prevention or treatment of liver disease using the same; and a method for preventing or treating liver disease.